Are we repeating the statin playbook with lipoprotein(a)?
In the late 1970s, a Japanese biochemist named Akira Endo discovered a compound from fungus that inhibited HMG-CoA reductase, the enzyme responsible for making cholesterol. It was an academic curiosity at the time. No one knew if lowering cholesterol would prevent heart attacks—it just lowered a number on a lab slip.
That compound eventually became lovastatin, and in 1987, Merck brought it to market with no proof of improved outcomes—only a …
Are we repeating the statin playbook with lipoprotein(a)?








![Why physicians must lead the design of artificial intelligence in health care [PODCAST]](https://kevinmd.com/wp-content/uploads/156891f3-d875-411e-9a3e-c50a13997d53-190x100.jpeg)
![Why weight regain is a predictable biological response after stopping GLP-1s [PODCAST]](https://kevinmd.com/wp-content/uploads/662faf85-c18d-47d3-8970-8f0e4231882f-190x100.jpeg)





![Politics and fear have replaced science in U.S. pain management [PODCAST]](https://kevinmd.com/wp-content/uploads/11c2db8f-2b20-4a4d-81cc-083ae0f47d6e-190x100.jpeg)





